NCT05840068

IGF Level in Breast Cancer Patients Treated With Metformin

Metformin Effect as a Chemotherapeutic Adjuvant on Level of IGF in Non-diabetic Breast Cancer Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 107 (actual)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to examine the impact of metformin as an adjuvant to chemotherapy on IGF levels in both progressing and non progressing cases of metastatic breast cancer in female patients.

Detailed description

One hundred and seven women with metastatic breast cancer (MBC) are randomly assigned to either a metformin (500 mg twice daily) or placebo (placebo) group during chemotherapy. All patients followed the standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI). Blood IGF-1 levels were measured at the start of treatment (baseline) and again six months later.

Conditions

• Breast Cancer Female

Interventions

Type	Name	Description
DRUG	MetFORMIN 500 Mg Oral Tablet	MetFORMIN 500 Mg Oral Tablet
DRUG	Chemotherapy	The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).

Timeline

• Start date: 2020-06-01
• Primary completion: 2021-07-31
• Completion: 2021-07-31
• First posted: 2023-05-03
• Last updated: 2023-05-03

Locations

1 site across 1 country: Egypt